1-3 of 3
Keywords: Tyrosine kinase inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Subject Area:
Dermatology , Immunology and Allergy
Anisha B. Patel, Alvin R. Solomon, Michael J. Mauro, Benjamin D. Ehst
Journal: Dermatology
Dermatology (2016) 232 (1): 122–125.
https://doi.org/10.1159/000437383
Published Online: 10 September 2015
...Anisha B. Patel; Alvin R. Solomon; Michael J. Mauro; Benjamin D. Ehst Background: Recently developed tyrosine kinase inhibitors (TKIs) offer first-line alternatives to patients with chronic myeloid leukemia. While these medications are generally well tolerated, cutaneous reactions occur frequently...
View article titled, Unique Cutaneous Reaction to Second- and Third-Generation <span class="search-highlight">Tyrosine</span> <span class="search-highlight">Kinase</span> <span class="search-highlight">Inhibitors</span> for Chronic Myeloid Leukemia
Open the PDF for Unique Cutaneous Reaction to Second- and Third-Generation <span class="search-highlight">Tyrosine</span> <span class="search-highlight">Kinase</span> <span class="search-highlight">Inhibitors</span> for Chronic Myeloid Leukemia in another window
Journal Articles

Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?

Subject Area:
Dermatology , Immunology and Allergy
Tobias R. Overbeck, Frank Griesinger
Journal: Dermatology
Dermatology (2012) 225 (2): 179–182.
https://doi.org/10.1159/000342786
Published Online: 20 October 2012
.... A therapeutic effect of VEGFR tyrosine kinase inhibitors in inflammatory skin disorders such as psoriasis was also postulated by Halin et al. [ 16 ]. 6 07 2012 21 08 2012 20 10 2012 © 2012 S. Karger AG, Basel 2012 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved...
View article titled, Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?
Open the PDF for Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy? in another window
Journal Articles

Generalized Xerotic Dermatitis with Neutrophilic Spongiosis Induced by Erlotinib (Tarceva®)

Subject Area:
Dermatology , Immunology and Allergy
J. Lübbe, I. Masouyé, P.-Y. Dietrich
Journal: Dermatology
Dermatology (2008) 216 (3): 247–249.
https://doi.org/10.1159/000112936
Published Online: 09 January 2008
...J. Lübbe; I. Masouyé; P.-Y. Dietrich Erlotinib is a small molecule tyrosine kinase inhibitor that is used as an anticancer agent. Most patients develop a pustular facial dermatitis within the first week of treatment. Pyogenic granulomas of the nail folds are another typical adverse event occurring...
View article titled, Generalized Xerotic Dermatitis with Neutrophilic Spongiosis Induced by Erlotinib (Tarceva®)
Open the PDF for Generalized Xerotic Dermatitis with Neutrophilic Spongiosis Induced by Erlotinib (Tarceva®) in another window